Novartis faces drug pipeline test with valuation premium in focus
By Bhanvi Satija LONDON, July 20 (Reuters) - Novartis investors will look beyond Tuesday's quarterly results for indications about three major drug trial readouts due in the second half of the year seen as vital to justifying the Swiss drugmaker's premium valuation. 
